AEON (aeonbiopharma.com) שווי פירמה כולל

Price action history on the GURU.Markets platform shows that the enterprise value of AEON Biopharma (AEON) is 11.72. AEON Biopharma (AEON) is developing a neurotoxic drug with low production costs, ensuring high profitability. Management is currently adjusting its research strategy following tests of new platforms. Business revenues rely on raising capital to study therapies for migraines and muscle pathologies.

The stability of the US legal regime and the protection of AEON Biopharma patents make its valuation more transparent, reducing risk premiums in the overall business assessment. Enterprise Value is calculated as the sum of market capitalization and net debt, reflecting the actual cost of acquiring the asset, where an increase in this metric signals the expansion of the company's scale but requires analysis to ensure there is no overpayment.